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Available online 20 May 2019The shortcomings of conventional tuberculosis treatments resulting from the development of drug resistance in
Mycobacterium tuberculosisdrive a need for the formulation of novel therapeutic agents. The diarylquinoline class
of drugs such as bedaquiline was recently approved for the treatment of multidrug-resistant strains of tubercu-
losis, primarily targeting c and ε subunits of the ATP synthases. Yet resistance to bedaquiline has already been re-
ported. Therefore, Rv1311 was used as the target for the identification of possible inhibitors against the
M. tuberculosis. The structure of Rv1311 was predicted and common feature pharmacophore models were gen-
erated which facilitated the identification of potential inhibitors in the ZINC database. The activities of the se-
lected molecules were compared with known inhibitors of the ATP synthase using quantitative structure–
activity relationship. The ZINC classified inhibitors showed comparable predicted activities with that of known
inhibitors. Furthermore, the inhibitory behavior of the studied drug molecules was experimentally determined
using in vitro techniques and showed the minimum inhibitory concentration as low as 25 μM. The resulted out-
comes provide a deeper insight into the structural basis of Rv1311 inhibitions and can facilitate the process of
drug design against tuberculosis.






Molecular dynamic simulations1. Introduction
Effective treatment and control of Mycobacterium tuberculosis, the
causative agent of tuberculosis (TB) has remained a global challenge es-
pecially in terms of drug resistance [1,2]. However, the incidence rates
of multidrug-resistant TB (MDR-TB) have sharply increased, placing
huge demands on TB healthcare programs [3]. Treatment options for
TB have remained stagnant over the past 50 years, which has contrib-
uted to the burden of drug resistance. In order to provide an efficient
therapy for MDR TB, the FDA recently approved the use of bedaquiline
as a new anti-TB drug [4,5]. Bedaquiline (TMC207) is a diarylquinoline
derivative andwas designed to inhibit ATP synthase. ATP synthase is es-
sential for the optimal growth ofM. tuberculosis as it is a key enzyme in-
volved in energymetabolism and is thus regarded as a promising target
for anti-TB drugs [6,7]. It catalyzes the production of ATP by using the
energy amassed in the formof difference in the transmembrane electro-
chemical potential of a coupling ion [8]. The bacterial ATP synthasenit, South African National
Private Bag X17, Bellville 7535,
ristoffels.sanbi.ac.za
. This is an open access article undercomprises a membrane-bound Fo segment which is composed of
a1b2c10–15 subunits as well as a hydrophilic F1 component containing
α3β3γδε subunits (Fig. 1) [8]. The passage of proton ions across Fo acti-
vates the conformational changes leading to the rotation of oligomeric
subunit c, coupled with the rotation of ε as well as γ subunits within
the α3β3 hexamer of F1 forces the synthesis of ATP [8].
In pathogenic bacteria, the proteins involved in energy metabolic
pathways aremostly unexplored as drug targets [9–11]. The ATP in bac-
teria is produced by oxidative phosphorylation using the respiratory
chain as well as by substrate-level phosphorylation of fermentable car-
bon sources [9,10]. The ATP synthase in these pathogenic bacteria may
incorporate special functionalities which facilitate their survival in en-
ergy deficit conditions [8]. Despite the down-regulation of ATP synthase
in the dormant condition, this group of enzyme can still be used as a
drug target inM. tuberculosis [8,12]. In the previous study, we identified
nine putative gene targets inM. tuberculosis by using genome and met-
abolic pathway mapping [13]. Therefore, we selected Rv1311 (epsilon
(ε) subunit) (Fig. 1) which is involved in the regulation of the ATP syn-
thase by affecting the efficiency of component coupling, along with the
induction of the catalytic pathway aswell as involved in the selective in-
hibition of ATP hydrolysis [14]. Bedaquiline is primarily designed to tar-
get the c subunit of the ATP synthase [15], but can also perform by
inhibiting the activity of ε subunit [16].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1.The diagrammatic representation of functional subunits present in theATP synthase
ofM. tuberculosis. The ATP synthase is divided into two functional domains F1 and Fo. The
Fo include a1b2c10–15 subunits while F1 consist of α3β3γδε subunits.
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thase ε chain inhibitors through structural analyses andpharmacophore
modeling because of the bedaquiline resistance mechanisms in
M. tuberculosis [17]. In the primary steps, the common feature
pharmacophore models were generated for the Rv1311-ATP complex
and 35 potential inhibitory molecules are sharing the respective fea-
tures were identified in the ZINC database. The 35 classified drug mole-
cules were subjected to virtual screening and the drug molecules with
the highest predicted binding affinities (ZINC65375075 and
ZINC11592624)were selected for further studies. Each resultant docked
system was subjected to 100 ns molecular dynamics (MD) simulations
in explicit water conditions, in order to validate the generated interac-
tion patterns and for the retrieval of the lowest energy conformations.
Furthermore, the respective drugs were purchased and tested using
an in vitro growth inhibition assay. The generated outcomes provide
an insight into the structural inhibition of Rv1311 and can facilitate
the process of drug design and discovery.
2. Materials and methods
2.1. Structural modeling and quality assessment
No experimentally resolved three dimensional (3-D) structures are
available for Rv1311 in Protein Data Bank (PDB). Therefore, its sequence
(UniProt ID - P9WPV1) was modeled using “PRIME” homology model-
ingmodule of Schrödinger [18,19]. Due to high amino acid conservation
of P9WPV1 predicted using ConSurf server [20], it was selected as a
model sequence for the current study. The generated 3-D structures of
Rv1311were further subjected to optimization tools for energyminimi-
zation, side chain as well as loop refinement. The stereochemical quali-
ties of the predicted structures were assessed using the Ramachandran
plots as well as on the basis of generated DOPE scores. The structures of
designed ligands were constructed by means of drawing utilities pres-
ent in the MAESTRO (Schrödinger Release 2018-1: Maestro,
Schrödinger, LLC, New York, NY, 2018) and the geometries of the resul-
tant ligand structures were optimized by using the Density Functional
Theory (DFT)method present in JAGUAR [21]. The generated structures
were subjected to further interaction studies.
2.2. Pharmacophore modeling
The potential scaffolds for Rv1311 were discovered using the
pharmacophore space modeling techniques available in Discovery Stu-
dio (DS) 2016. The “Receptor - Ligand Pharmacophore Generation”module in DS was used for the generation of selective pharmacophore
model from Rv1311-ATP complex. The models are generated from the
interaction features present in Rv1311-ATP. Themain objective of build-
ing the respective pharmacophoremodels is to identify the potential in-
hibitors that can bind strongly to the Rv1311. The best pharmacophore
hypothesis was used to screen the ZINC database (version 15), which
contain information about 120 million commercially available “drug-
like” compounds [22]. The search was set to 600 for “Best N Hits” in
the section “Limit Hits” in order to obtain the best chemical entities.
The generated list of molecules was further filtered using a number of
criterions to achieve thefinal potential inhibitorymolecules. The valida-
tion of the generated pharmacophore model was performed using
“Decoy set” and by analyzing the interaction between chemical features
and key amino acid. The decoys for each active molecule was identified
using DecoyFinder in ZINC database [23].
2.3. Molecular docking
The obtained list of drug molecules was subjected to virtual screen-
ing using AutoDock Vina [24]. The drug molecules with the highest af-
finities to Rv1311 were re-docked using AutoDock 4 [25] package,
which enables the calculation of the inhibitor constant. This software
performs the prediction of the bound conformation based on free en-
ergy, which was calculated on the basis of the empirical force field and
the Lamarckian Genetic Algorithm [25]. The AutoGrid module was
used to create a grid box of dimensions 129 × 94 × 104 Å along the
XYZ directions with a spacing of 0.375 Å. The efficiency of the predic-
tions was amplified by setting the parameters associated with the La-
marckian genetic algorithm to the maximum efficiency values. This
was achieved by setting a number of individuals in the population to
250 and the maximum number of energy evaluations to a “longer” in-
terval. The 100 docked conformations were generated for each
Rv1311 and ligand systems which were further grouped according to
the RMSD tolerance of 2.0 Å. The re-scoring of the generated conforma-
tions were performed on the basis of the scoring function present in
DrugScoreX server [26] and the docked conformation with the highest
score was selected for the Molecular Dynamics (MD) simulations.
2.4. Molecular dynamics (MD) simulations
The obtained docked complexes were subjected to MD simulations
using GROMACS 5.1.2 [27], and the topologies of the complexed struc-
tures were generated using the GROMOS96 53a6 force field [28]. The
GROMACS package lack an appropriate force field parameters for
drug-like molecules, therefore, the PRODRG server [29] was used for
the generation of topologies and coordinate files of the ligand mole-
cules. Furthermore, the partial charges in the generated topologies
were corrected using the DFT method implemented in GAUSSIAN
which utilized the B3LYP 6-31G (d,p) basis set and the CHELPG program
[30]. Afterward, all the docked complexes were solvated in the SPC/E
watermodel [31] aswell as the neutralizationwas performed by adding
the counterions. The NA and CL ions were added to neutralize the sys-
tems. Consequently, the neutralized systems were energetically mini-
mized by steepest descent and conjugate gradient algorithms with a
convergence criterion of 0.005 kcal/mol and the restraints were applied
to the structure of the ligands before the equilibration phase.
The equilibration step was performed in NVT (constant volume) as
well as NPT (constant pressure) ensemble conditions, each with a
100 ps time scale. The temperature of the system was maintained at
300 K using Berendsen weak couplingmethod in both ensemble condi-
tions as well as the pressure, whichwasmaintained at 1 bar by utilizing
Parrinello-Rahman barostat in constant pressure ensemble. The final
MD simulations were produced using the LINCS algorithm for 100 ns
timescale. The generated trajectories were used to analyze the behavior
of each complex in the explicit water environment. The deviations in
the distances, H-bonds, RMSD (Root Mean Square Deviations), and
Fig. 3. The generated pharmacophore model showing the classified chemical features and e
(AAADDN) along with 72 features identified in the ligand molecule (HB_ACCEPTOR: 50, HB_D
Fig. 2. The predicted structure of Rv1311 showing characteristic N-Terminal β sandwich
domain which is present up to first 85 residues containing eight β strands and C-
terminal Domain extending from residues 92–120 consist of two α-helices.
584 M. Shahbaaz et al. / International Journal of Biological Macromolecules 135 (2019) 582–590Radius of Gyration (Rg) were analyzed between the complexed protein
and ligand. Furthermore, the free energy of binding was calculated
using Molecular mechanics Poisson–Boltzmann surface area (MM-
PBSA) protocols implemented in the g_mmpbsa package [32] which
provide deeper insights into the interactionmechanisms of the proteins
and the ligand molecules.
2.5. In vitro studies
2.5.1. Bacterial strains and growth conditions
Mycobacterium tuberculosisH37Rv (ATCC 27294) strain carrying the
plasmid pCHERRY 3 (a gift from Tanya Parish (Addgene plasmid #
24659; http://n2t.net/addgene:24659; RRID:Addgene_24659), H37Rv:
pCHERRY) [33] was cultured in Middlebrook 7H9 liquid media (Becton
Dickinson, USA) supplemented with 0.2% (v/v) glycerol (Merck
Laboratories, USA), 0.05% Tween 80 (Sigma-Aldrich, Germany) and
10% albumin-dextrose-catalase (ADC) (Becton Dickinson, USA), with
50 μg/mL hygromycin B in filtered screw cap tissue culture flasks
(Greiner Bio-one, Germany). Wild-typeM. tuberculosis H37Rv was cul-
tured in the same media, but without hygromycin B. The cultures
were incubated at 37 °C until an optical density (OD600) of 1.0) was
reached.
2.5.2. Drug testing
The two compounds (ZINC65375075 and ZINC11592624) with the
highest binding affinities were purchased from Molport, USA and
VITASMLAB, respectively. Both compounds were dissolved in Dimethyl
sulfoxide (DMSO) and diluted to obtain final concentrations of 50, 25ssential interacting amino acids. The 6 features match the receptor-ligand interactions
ONOR: 13, NEG_IONIZABLE: 3 and RING_AROMATIC: 4).
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added to the appropriate wells. Positive, negative and compound
controls were included on each plate. The positive control contained
100 μg/mL rifampicin and H37Rv:pCHERRY3. The negative controls in-
cluded wells containing media only to identify contamination and an
untreatedfluorescence control to determine that DMSOused to dissolve
the compounds did not affect growth. A compound control included the
final concentration of each compound in the absence of M. tuberculosis
to confirm the absence of autofluorescence. The background control
contained M. tuberculosis H37Rv (without reporter) which is used to
subtract thefluorescencemeasurement to account for the inherentfluo-
rescence of H37Rv. An undiluted H37Rv:pCHERRY3 control was used to
set the gain during fluorescencemeasurement. Plateswere incubated at
37 °C and readings were taken at time 0 and at 24-hour intervals there-
after for five days using the BMG Labtech POLARstar Omega plate reader
(BMG Labtech, Germany, excitation: 587 nm, emission: 610 nm). The
experiment was replicated three times to ensure the validity of the
results.
3. Results and discussion
The revival of TB drug research and development is primarily driven
by the urgent need for global eradication of the disease aswell as thede-
velopment of novel and more efficient therapies against drug-resistant
strains [34]. Accordingly, a variety of therapeutic products are now in
the diverse stages of clinical trials, and numerous drug development
projects are in the pipelines, with varying degrees of success [34]. It is
evident that the integration of the computational approaches with the
experimental workflows can accelerate TB drug discovery [35].
Previous studies by our group aimed to elucidate drug resistance
mechanisms present in M. tuberculosis by using genome and metabolic
pathway mapping which led to the identification of nine putative tar-
gets, which could be used for the development of novel therapeutic
agents [13]. In this study, Rv1311 was used for the identification ofFig. 4. The resulted docked conformation showing (A) The interaction pattern generated for th
minimized pose for Rv1311_Beda complex. (Rv1311_27, Rv1311_35 and Rv1311_Beda rep
ZINC11592624 as well as Bedaquiline respectively).candidate therapeutic agents against TB, as it is crucial for the function-
ing of TB ATP synthase [8]. Therefore, the structure of Rv1311 was pre-
dicted and the pharmacophore models were generated. The database
searching using these pharmacophore hypotheses leads to the identifi-
cation of 35 respective inhibitory features carrying agents. These mole-
cules were subjected to the virtual screening against the ligand binding
site of Rv1311, and the top two inhibitors with highest binding affinities
were selected for the further studies which are discussed in the follow-
ing sections:
3.1. Assessments of generated structures
In the primary analyses, the homologous templates were identified
in Protein Data Bank (https://www.rcsb.org/, PDB) using BLAST
searching algorithms. The database search identified epsilon subunit
and ATP complex of F1F0-ATP synthase from the thermophilic Bacillus
PS3 (PDB ID – 2E5Y) with a sequence identity of 37% as well as epsilon
subunit of F1F0-ATP Synthase from Escherichia coli (PDB ID – 1AQT,
identity 26%) as the possible template. The 3D coordinates of Rv1311
were predicted by satisfying the spatial restraints using MODELLER
[36]. The predicted structure of Rv1311 contains two domains, an N-
terminal β sandwich (containing eight β strands) as well as C-
terminal α helices domain (Fig. 2). All the β strands were arranged in
an anti-parallel manner in the β sheet, while the hydrophobic space be-
tween the two α helices forms an alanine zipper resembling structure
(Fig. 2). The stereochemical validation using PROCHECK showed the
presence of 95.2% residues in the allowed region of the Ramachandran
plot while 4.8% were occupied in the disallowed regions. The Rv1311
model was categorized as “Pass” in both Verify 3D [37] and
WHATCHECK (https://swift.cmbi.umcn.nl/gv/whatcheck/) servers. The
ProQ server [38] was used for predicting the quality of the generated
Rv1311 model, computed the LGscore of 3.542 and MaxSub value of
0.192 and classified it in “very good model” category. The quality of
the predicted 3D model was further verified using ProSA server [39]e complex of Rv1311_27. (B) Selected pose of complex Rv1311_35. (C) The energetically
resent the docked complexes between Rv1311 protein and inhibitors ZINC65375075,
Table 1



























1. Rv1311_27 25 −4.41 581.56 −0.28 −3.23 −6.2 −0.38 1.79
2. Rv1311_35 10 −5.73 832.95 −0.14 −6.8 −6.89 −1.71 2.68
3. Rv1311_BEDA 11 −4.14 930.44 −0.11 −6.3 −6.82 −3.67 2.68
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teins of similar size. In order to improve the quality of the generated
models, they were further subjected to the side chain optimization
and for the steric clashes refinements. The RMSD values of 1.453 Å
and 1.013 Åwere calculated after superimposition of Rv1311 with tem-
plates 1AQT and 2E5Y respectively. These observations indicated the re-
liability of the predicted model; therefore, further analyses were
performed.
3.2. Pharmacophore feature analyses
The structure of Rv1311-ATP complex was predicted and the
receptor-ligand pharmacophore generation modules lead to the devel-
opment of 10 hypotheses using the structure of Rv1311-ATP complex.
Around 70 features were identified in the ligand ATP, while six features
were predicted to match the Rv1311-ATP interactions (Fig. 3). The
pharmacophore_01 was selected because the selectivity score was cal-
culated to be around 11.098 for the respective model. The five features
were observed in this model, namely, two hydrogen bond acceptors,
two hydrogen bond donors and one negative ionizable feature (Fig. 3).
The hydrogen bonds within a distance of 3.0 Å between the Rv1311
and ATP were identified and retained in the generated model.Fig. 5. (A)–(C) The graphical illustration of changes observed in the pattern of hydrogen bondin
simulations. (Rv1311_27, Rv1311_35 and Rv1311_Beda represent the docked complexes betw
respectively).Moreover, the hydrophobic features on the ATP within 5.5 Å of the cen-
troid of hydrophobic residues were included, while for the prediction of
positive or negative ionizable features, the charge interactions within
5.6 Åwere involved in the hypothesis. Therefore, the generated hypoth-
esis was used for searching suitable inhibitors in the ZINC database. The
35 respective features containing potential inhibitory molecules were
identified, which are subjected to further screening.
The validation of the generated pharmacophore model was per-
formed using the decoy set. Around 24 active inhibitors of ATP synthase
was collected from the literature [40–42] and a set of 864 decoys were
identified in ZINC database using DecoyFinder. The active molecules
and the decoys were mixed to form a single set of molecules, which
were screened using the generated pharmacophore model. It was ob-
served that the model differentiate the actives and inactive molecules
with an accuracy of 93.13%. The true positive (TP), true negative (TN),
false positive (FP) and false negative (FN) values were found to be 23,
804, 60 and 1 respectively. The true positive rates and false positive
rates was used for calculating ROC curve (Fig. S1). The area under
curve (AUC) and BEDROC values were calculated to be around 0.942
and 0.656. These generated parameters indicated the reliability of
pharmacophoremodelwhich classify the activemoleculeswithhigh ac-
curacy. Furthermore, the interactions between chemical features andg in the complexes of Rv1311 and the concerned inhibitors during the course of 100 nsMD
een Rv1311 protein and inhibitors ZINC65375075, ZINC11592624 as well as Bedaquiline
Fig. 7. The curves highlighting (A) the changes in the RMSD values for each studied
complexes. (B) The changes in the radius of gyration corresponding to the deviation in
the conformational behavior of the studied docked complexes. (Rv1311_27, Rv1311_35
and Rv1311_Beda represent the docked complexes between Rv1311 protein and
inhibitors ZINC65375075, ZINC11592624 as well as Bedaquiline respectively).
Fig. 6. The graphical depiction of (A) The changes observed in the distances between
Rv1311 and the complexed ligand molecules. (B) The fluctuations of the constituent
residues involved in the interaction of the Rv1311 with the ligand molecules in the
studied complexed systems. (Rv1311_27, Rv1311_35 and Rv1311_Beda represent the
docked complexes between Rv1311 protein and inhibitors ZINC65375075,
ZINC11592624 as well as Bedaquiline respectively).
587M. Shahbaaz et al. / International Journal of Biological Macromolecules 135 (2019) 582–590key amino acids were analyzed and the Glu85 which may form the ac-
tive site of the Rv1311 was included in the Hydrogen bond donor fea-
ture of the pharmacophore model (Fig. 3).
3.3. Structure activity relationship (SAR) studies
In order to evaluate the inhibitory efficiency of the classified inhibi-
tors, a 3D Quantitative structure–activity relationship (3D-QSAR) was
performed. The structures and activity information of ATP synthase in-
hibitors was collected from the literature [40–42]. The structures of in-
hibitors were constructed using the drawing utilities of Discovery
Studio (DS) and then minimized using the optimization modules. The
structures of the ligands were subjected to “Prepare Ligands for QSAR”
module which prepare the dataset for further steps. The Minimum In-
hibitory Concentration (MIC) was selected as the dependent variable
and the dataset was divided into the “Training” and “Test” sets. Conse-
quently, the 3D-QSAR model was constructed using “Create 3D QSAR
model” module of the DS, with 5 fold cross validations. The R2 and Q2
values for the generated model was observed to be 0.996 and 0.612 re-
spectively, indicating the reliability of the predicted model. The activi-
ties of compounds 27 and 35 were predicted to be around 0.147
μg/mL and 0.130 μg/mL respectively, which was falling in the range of
0.138–0.217 μg/mL calculated for known ATP synthase inhibitors
using generated 3D-QSAR model. These observations indicated that
these studied molecules have potential to inhibit the functionalities of
ATP synthase.3.4. Rv1311 interaction profiles
The 35 classified drug compounds were subjected to virtual screen-
ing using AutoDock Vina. The top two derivatives with highest binding
affinities were selected for further studies, and bedaquiline was used as
a control. The compounds were re-docked using AutoDock suite in
order to validate the generated outcomes. The information about the ac-
tive site of Rv1311 was deduced by comparing with the structure of the
template (PDB ID – 2E5Y). Similar to other bacterial ε subunit, Asp91
(corresponding to Asp89 of the template) may form a major portion
of the ATP binding motif andmay be involved in recognition of adenine
ring of ATP [43]. The Asp has completely conserved in the respective
motif and its side chain is responsible for the fitting of ATP in the correct
orientation by providing an electrostatic repulsion against triphosphate
groups [43]. In addition, the Glu85 (corresponding to Glu83)may play a
significant role andmay be involved in the formation of adenine pocket,
due to the presence of long side chain [43]. Furthermore, theGlu residue
can also be involved in the stabilization of ribose by providing the hy-
drogen bonding and is responsible for increasing the binding affinity
of the ATP [43]. Glu85 may also provide stabilization to the orientation
of the C-terminal domain (CTD) relative to the N-terminal domain
(NTD) through the hydrogen bonding [43].
Therefore, the grid center was focused on Glu85 and Asp91. For
Rv1311_27 (docked system of Rv1311 protein and ZINC65375075)
complex, the residues Glu85, ILE 90, Ala94, and Ala95 was observed in
the binding pocket (Fig. 4A) with the free energy of binding of
−4.41 kcal/mol and inhibition constant was predicted to be around
581.56 μM(Table 1). Moreover, in complex Rv1311_35 (Docked system
588 M. Shahbaaz et al. / International Journal of Biological Macromolecules 135 (2019) 582–590of Rv1311 protein and ZINC11592624), the residues Asp91 was ob-
tained along with Ala94 and Arg113 in the binding pocket (Fig. 4B),
the free energy of binding and inhibition constant was calculated to be
around −5.73 kcal/mol and 832.95 μM respectively (Table 1). In addi-
tion, the performances of the studied inhibitors were validated through
comparison of the obtained parameters for Rv1311_Beda complex
(Docked system of Rv1311 protein and bedaquiline), which showed
Glu85, Glu89, Asp91 and Ala94 (Fig. 4C) in the interaction pocket with
the free energy of binding of −4.14 kcal/mol and inhibition constant
value of 930.44 μM. These observations indicated that the compound
35 is inhibiting comparably to bedaquiline as indicated by the generated
parameters (Table 1). Moreover, a comparison of the interaction affini-
ties was performed between the ATP and the studied compounds. The
ATP showed free energy of binding energy of −3.7 kcal/mol, which is
comparative lower than the studied inhibitors (Table 1). Therefore,
the inhibitors may compete with the ATP during the course of inhibi-
tion. All three docked systems were subjected to Molecular Dynamics
(MD) simulations for further analyses, which are discussed in the subse-
quent section.
3.5. Analyses of conformational dynamics' patterns
The conformational behaviors of the obtained docked complexes
were analyzed in the explicit water conditions using theGROMACS soft-
ware package, which provide a deeper insight into the dynamics of
structural and energetic changes. All the systemswere neutralized,min-
imized and well equilibrated, then subjected to 100 ns MD simulations.
In all the studied complexes, NA ions ranges from 20–30 to 13–22 CL
ionswere added to neutralized the systems. Consequently, they are sub-
jected to the subsequent stages of MD simulations. Then generatedFig. 8. (A)–(C) The MM-PBSA analysis of docked complexes, based resulted curves showing t
studied inhibitor molecules. (Rv1311_27, Rv1311_35 and Rv1311_Beda represent the docked
as Bedaquiline respectively).trajectories then analyzed using the utilities of the GROMACS. The
changes in the pattern of the hydrogen bonding between the Rv1311
and the studied inhibitors were analyzed using “gmx hbond” module.
In the Rv1311_27 complex, amaximum of five hydrogen bondswas ob-
served in the system (Fig. 5A). While the highest number of eight H-
bonds was obtained in the Rv1311_35 complex as a comparison with
Rv1311_Beda which shows the presence of four bonds (Fig. 5B and C).
Furthermore, the “gmx pairdist”wasused for the calculation of distances
betweenRv1311 and the concerned inhibitors. The average distance be-
tweenRv1311 and inhibitors 27, 35 aswell bedaquilinewas observed to
be around 0.260 nm, 0.292 nm, and 0.247 nm respectively. But in com-
plex Rv1311_27, very high fluctuations in the distance values were ob-
served between 20 ns – 25 ns, indicating the unstable nature of the
complex, while the rest of the systems are showing relatively stable na-
ture of binding (Fig. 6A). Moreover, the fluctuations in the constituent
residues were compared for each system (Fig. 6B). The residues of com-
plex Rv1311_27 showed relatively higher fluctuations as compared to
Rv1311_35 and Rv1311_Beda, particularly in the region between the
residues Glu85 and Asp91(Fig. 6B).
Consequently, the stability and compactness of the resulted complex
systems were assessed using generated RMSD and Radius of Gyration
(Rg) values. In complex Rv1311_27, relatively higher fluctuations in
the RMSD values were observed between 0.3 and 0.8 nm throughout
the course of 100nsMD simulations as compared to the rest of the stud-
ied systems, indicating the persistent instability in the system (Fig. 7A).
While stable comparative nature was observed in Rv1311_35 and
Rv1311_Beda systems, in which fluctuations were observed around
0.3 nm (Fig. 7A). Similar inferences were drawn from Rg plots, in
which consistent variations in the Rg curve were observed for
Rv1311_27 with the values ranges from 1.4 nm −1.5 nm (Fig. 7B).he behavior of the interactions in the form of binding affinities between the Rv1311 and
complexes between Rv1311 protein and inhibitors ZINC65375075, ZINC11592624 as well
Table 2
List of average energies computed using MM/PBSA technique during the course of MD
simulations.
S. No System Energies (kJ/mol)
Van der Waals Electrostatic Total
1. Rv1311_27 −8.090 −458.073 −466.163
2. Rv1311_35 −83.861 −197.459 −281.321
3. Rv1311_BEDA −99.004 −752.194 −851.198
589M. Shahbaaz et al. / International Journal of Biological Macromolecules 135 (2019) 582–590The Rv1311_Beda showed least values in the Rg plots with fluctuations
were observed around 1.4 nm, but Rg values for Rv1311_35 and
Rv1311_Beda showed convergence after 90 ns time (Fig. 7B). These ob-
servations indicated that both the systems were becoming relatively
stable by achieving the comparable compactness in their structural
topology.
The Molecular Mechanics Poisson-Boltzmann Surface Area (MM/
PBSA) methods are widely used techniques for estimating protein-
ligand binding affinities in the explicit solvent conditions because of
their efficiency as well as high correlation with experiment [44]. These
predictions based on the calculation of binding affinities are essential
in providing a solution for a wide range of biophysical challenges in-
volved in the analyses of protein-protein interactions and structure-
based drug design [45]. Therefore, the g_mmpbsa module was used for
the calculation of the binding affinities between the Rv1311 and the
concerned inhibitors. In the Rv1311_27 complex, the electrostatic en-
ergy is primarily contributing to the total energy of the system
(Fig. 8A), which showed high fluctuations around −500 kJ/mol.
While, in Rv1311_35 complex, the total energy was fluctuating in the
range of−100 kJ/mol to - 400 kJ/mol, with binding affinities were con-
tributed by both Van derWaals and electrostatic energies (Fig. 8B). Fur-
thermore, the highest binding affinities of around −1000 kJ/mol were
observed in Rv1311_Beda complex as compared to the other systems,
indicating the tightly binding nature of bedaquiline (Fig. 8C). The output
generated after MD simulations showed that Rv1311_35 is comparably
stable in comparison with Rv1311_Beda, in order to improve theFig. 9. The in vitro experiment based generated plots showing (A) The changes in the
growth pattern of M. tuberculosis when subjected to varied concentration of compound
27 (ZINC ID - ZINC65375075). (B) The growth dynamics of M. tuberculosis in the
presence of diverse concentrations of compound 35 (ZINC ID - ZINC11592624).binding affinities several modifications were required in the side of
compound 35. The average values of generated energies for each system
are listed in Table 2.
3.6. In vitro growth assays
To assess the in silico results, we performed in vitro assessment of
two of the available compounds in a whole cell assay. We purchased
two of the available top binding compounds (ZINC65375075 and
ZINC11592624) based on binding affinity scores and interaction analy-
sis from vendors. As a preliminary test, we aimed to identify inhibitors
with a Minimum Inhibitory Concentration of at least 50 μM or better.
Of the two compounds, ZINC65375075 (compound 27)was found to in-
hibitM. tuberculosis growth at 50 μM, 25 μM and slightly at 10 μM con-
centrations (Fig. 9A). Whereas, compound 35 showed slight inhibition
at 50 μMwith bacteria sustain its growth in the rest of the concentration
(Fig. 9B). The limitedperformance of these selecteddrugsmay be attrib-
uted to the restricted cell permeability. In order to understand the var-
iation of M. tuberculosis growth inhibition, the rifampicin control was
added to the assay (Fig. 9). These findings suggest that the in silico
screening method has merit in identifying novel anti-TB compounds
and will help in making drug discovery more affordable. Future work
will include in silico modifications of compound ZINC11592624 to im-
prove binding affinity and virtual screening for isomers of
ZINC11592624 that are commercially available to test in vitro.
4. Conclusions
In this study, the Rv1311 (ε subunit) was selected as a drug target
because it is essential for the functioning of the ATP synthase and thus
crucial for the energy generation in M. tuberculosis. The structure of
Rv1311was predicted and thepharmacophoremodelingperformeden-
abled the identification of 35 novel inhibitors in the ZINC database.
These inhibitors were subjected to virtual screening against Rv1311
and subsequently, to a variety of MD simulation techniques. This leads
to the identification of derivatives with the highest binding affinities
against Rv1311. Bedaquiline was used as a control which provides the
deeper insight into the inhibition of Rv1311 and the most suitable
docking complex was selected through comparison with the
bedaquiline complex. Our in silico finding were validated using in vitro
experimentswhich showed ZINC11592624 is responsible for the reduc-
tion of M. tuberculosis growth in culture medium. This study will facili-
tate the development of novel inhibitors against the ATP synthase of
M. tuberculosis and can also help in the development of therapies
against drug-resistant strains.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijbiomac.2019.05.108.
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